VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study

作者：Sun Young Rha, L.S. Wyrwicz, P.E. Yanez Weber, Yibing Bai, M.H. Ryu, J. Lee, F. Rivera, G.V. Alves, Marcelo Garrido, K-K. Shiu, M. González Fernández, J. Li, M. Lowery, T. Çil, F.J.S.M. Cruz, S. Qin, L. Yin, S. Bordia, P. Bhagia, D-Y. Oh · 发表于：Annals of Oncology · 年份：2023 · DOI：10.1016/j.annonc.2023.01.006 · 被引用次数：67 · 研究领域：Gastric Cancer Management and Outcomes、Cancer Immunotherapy and Biomarkers、Esophageal Cancer Research and Treatment